Browsing Clinical Studies by author "Gillman, Alexa"
Now showing items 1-9 of 9
-
Accelerated versus standard epirubicin followed by CMF versus capecitabine as adjuvant therapy of breast cancer: results of the randomised UK TACT2 trial (CRUK/05/19)
Bliss, J; banerji, J; Gillman, A; Morden, J -
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Cameron, D; Morden, JP; Canney, P; Velikova, G; Coleman, R; et al. (ELSEVIER SCIENCE INC, 2017-07-01)BACKGROUND: Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2×2 factorial design to test two hypotheses: whether use of accelerated epirubicin would improve ... -
Biomarker-guided trials: Challenges in practice.
Antoniou, M; Kolamunnage-Dona, R; Wason, J; Bathia, R; Billingham, C; et al. (ELSEVIER INC, 2019-12-01)Biomarker-guided trials have drawn considerable attention as they promise to lead to improvements in the benefit-risk ratio of treatments and enhanced opportunities for drug development. A variety of such designs have been ... -
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
Goodall, J; Mateo, J; Yuan, W; Mossop, H; Porta, N; et al. (AMER ASSOC CANCER RESEARCH, 2017-09-01)Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity ... -
Considerations when introducing electronic patient-reported outcome data capture in multicentre oncology randomised controlled trials.
Philipps, L; Foster, S; Gardiner, D; Gillman, A; Haviland, J; et al. (BMC, 2022-12-12) -
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Mateo, J; Carreira, S; Sandhu, S; Miranda, S; Mossop, H; et al. (MASSACHUSETTS MEDICAL SOC, 2015-10-29)BACKGROUND: Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would ... -
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation.
Gellert, P; Segal, CV; Gao, Q; López-Knowles, E; Martin, L-A; et al. (NATURE PORTFOLIO, 2016-11-09)Pre-surgical studies allow study of the relationship between mutations and response of oestrogen receptor-positive (ER+) breast cancer to aromatase inhibitors (AIs) but have been limited to small biopsies. Here in phase I ... -
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey.
Lorente, D; Ravi, P; Mehra, N; Pezaro, C; Omlin, A; et al. (ELSEVIER, 2018-03-01)BACKGROUND: Evaluation of responses to treatment for metastatic castration-resistant prostate cancer (mCRPC) remains challenging. Consensus criteria based on prostate-specific antigen (PSA) and clinical and radiologic ... -
What are the main inefficiencies in trial conduct: a survey of UKCRC registered clinical trials units in the UK
Duley, L; Gillman, A; Duggan, M; Belson, S; Knox, J; et al. (Springer Science and Business Media LLC, 2018-12-01)